Schedule 13D - Activist Investments
NYSE
Fresenius Medical Care Holdings, Inc. and Fresenius Medical Care AG updated their Schedule 13D filing for Humacyte, Inc., reporting a decreased beneficial ownership percentage due to share dilution and announcing key management changes within Fresenius.
Capital raise
Worse than expected
NYSE
Fresenius Medical Care AG's beneficial ownership in Humacyte, Inc. decreased to 9.9% due to an increase in Humacyte's outstanding shares following a recent offering.
Capital raise
NYSE
SCHEDULE 13D/A: Fresenius KGaA Reduces Stake in Fresenius Medical Care AG to 28.6% Following Share Placement
Fresenius SE & Co. KGaA has reduced its beneficial ownership in Fresenius Medical Care AG to approximately 28.6% after selling 10.6 million shares in an accelerated book building process.
Capital raise
NYSE
SCHEDULE 13D/A: Fresenius SE & Co. KGaA Executes Strategic Portfolio Optimization with Fresenius Medical Care AG Share Placement and Exchangeable Bond Offering
Fresenius SE & Co. KGaA is strategically reducing its stake in Fresenius Medical Care AG through a share placement and the issuance of exchangeable bonds, aiming for portfolio optimization and enhanced financial stability.
Capital raise
Schedule 13G - Passive Investments
NYSE
BlackRock, Inc. has reported a beneficial ownership of 5.00% in Fresenius Medical Care AG, holding 13,447,914 shares.
NYSE
Investment firm Harris Associates L.P. and its general partner, Harris Associates, Inc., have disclosed a passive beneficial ownership of 3.9% in Fresenius Medical Care AG, totaling 11,717,575 ordinary shares.